136 related articles for article (PubMed ID: 35559797)
1. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
2. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival.
Brundage MD; Booth CM; Eisenhauer EA; Galica J; Kankesan J; Karim S; Koven R; McDonald V; Ng T; O'Donnell J; Ten Hove J; Robinson A
J Natl Cancer Inst; 2023 Dec; 115(12):1526-1534. PubMed ID: 37458509
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Hurvitz SA; Lalla D; Crosby RD; Mathias SD
Breast Cancer Res Treat; 2013 Dec; 142(3):603-9. PubMed ID: 24218050
[TBL] [Abstract][Full Text] [Related]
5. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
Postmus D; Litiere S; Bogaerts J; Versluis J; Cornelissen JJ; Pignatti F
Eur J Cancer; 2024 Jan; 197():113496. PubMed ID: 38134481
[TBL] [Abstract][Full Text] [Related]
6. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
7. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
8. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.
Mertz S; Benjamin C; Girvalaki C; Cardone A; Gono P; May SG; Comerford E; Than KS; Birch K; Roach M; Myers S; Sasane M; Lavi L; Cameron A; Cardoso F
Breast; 2022 Oct; 65():84-90. PubMed ID: 35870420
[TBL] [Abstract][Full Text] [Related]
9. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
10. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
[TBL] [Abstract][Full Text] [Related]
11. Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.
Johnson KR; Liauw W; Lassere MN
Ann Oncol; 2015 Mar; 26(3):485-96. PubMed ID: 25057168
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
13. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.
Liu LY; Yu H; Bai JL; Zeng P; Miao DD; Chen F
Asian Pac J Cancer Prev; 2015; 16(3):1001-6. PubMed ID: 25735320
[TBL] [Abstract][Full Text] [Related]
14. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
16. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.
Raphael MJ; Robinson A; Booth CM; O'Donnell J; Palmer M; Eisenhauer E; Brundage M
JAMA Oncol; 2019 Dec; 5(12):1779-1789. PubMed ID: 31556921
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
18. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
19. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
20. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
